{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:53:09Z","timestamp":1785509589516,"version":"3.56.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s40257-021-00604-9","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T16:03:09Z","timestamp":1620230589000},"page":"541-554","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes"],"prefix":"10.1007","volume":"22","author":[{"given":"Jonathan I.","family":"Silverberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Thyssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"St\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan","family":"Valdez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Rojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinaki","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela E.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Feeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8333-4676","authenticated-orcid":false,"given":"Marco","family":"DiBonaventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,5]]},"reference":[{"issue":"5","key":"604_CR1","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jaci.2013.08.031","volume":"132","author":"JI Silverberg","year":"2013","unstructured":"Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132(5):1132\u20138.","journal-title":"J Allergy Clin Immunol."},{"issue":"1 Pt 1","key":"604_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0091-6749(99)70536-1","volume":"103","author":"H Williams","year":"1999","unstructured":"Williams H, Robertson C, Stewart A, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol. 1999;103(1 Pt 1):125\u201338.","journal-title":"J Allergy Clin Immunol."},{"issue":"3","key":"604_CR3","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","volume":"139","author":"ZC Chiesa Fuxench","year":"2019","unstructured":"Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139(3):583\u201390.","journal-title":"J Invest Dermatol."},{"issue":"3","key":"604_CR4","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340\u20137.","journal-title":"Ann Allergy Asthma Immunol."},{"issue":"8","key":"604_CR5","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1111\/jdv.16364","volume":"34","author":"JP Thyssen","year":"2020","unstructured":"Thyssen JP, Andersen Y, Halling AS, et al. Strengths and limitations of the United Kingdom Working Party criteria for atopic dermatitis in adults. J Eur Acad Dermatol Venereol. 2020;34(8):1764\u201372.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"1","key":"604_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","volume":"137","author":"AM Drucker","year":"2017","unstructured":"Drucker AM, Wang AR, Li WQ, et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26\u201330.","journal-title":"J Invest Dermatol."},{"issue":"3","key":"604_CR7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.det.2017.02.002","volume":"35","author":"JI Silverberg","year":"2017","unstructured":"Silverberg JI. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin. 2017;35(3):283\u20139.","journal-title":"Dermatol Clin."},{"issue":"4","key":"604_CR8","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jaip.2018.11.043","volume":"7","author":"JI Silverberg","year":"2019","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al. Health utility scores of atopic dermatitis in US adults. J Allergy Clin Immunol Pract. 2019;7(4):1246-52.e1.","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"1","key":"604_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/jdv.15919","volume":"34","author":"M Augustin","year":"2020","unstructured":"Augustin M, Langenbruch A, Blome C, et al. Characterizing treatment-related patient needs in atopic eczema: insights for personalized goal orientation. J Eur Acad Dermatol Venereol. 2020;34(1):142\u201352.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"3","key":"604_CR10","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1067\/mai.2003.174","volume":"111","author":"BG Bender","year":"2003","unstructured":"Bender BG, Leung SB, Leung DY. Actigraphy assessment of sleep disturbance in patients with atopic dermatitis: an objective life quality measure. J Allergy Clin Immunol. 2003;111(3):598\u2013602.","journal-title":"J Allergy Clin Immunol."},{"issue":"2","key":"604_CR11","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1111\/j.1468-3083.2012.04578.x","volume":"27","author":"D Chrostowska-Plak","year":"2013","unstructured":"Chrostowska-Plak D, Reich A, Szepietowski JC. Relationship between itch and psychological status of patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2013;27(2):e239\u201342.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"2","key":"604_CR12","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jaci.2012.10.041","volume":"131","author":"P Yaghmaie","year":"2013","unstructured":"Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol. 2013;131(2):428\u201333.","journal-title":"J Allergy Clin Immunol."},{"issue":"12","key":"604_CR13","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1038\/jid.2015.337","volume":"135","author":"SH Yu","year":"2015","unstructured":"Yu SH, Silverberg JI. Association between atopic dermatitis and depression in US adults. J Invest Dermatol. 2015;135(12):3183\u20136.","journal-title":"J Invest Dermatol."},{"issue":"1","key":"604_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/jid.2014.325","volume":"135","author":"JI Silverberg","year":"2015","unstructured":"Silverberg JI, Garg NK, Paller AS, et al. Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. J Invest Dermatol. 2015;135(1):56\u201366.","journal-title":"J Invest Dermatol."},{"issue":"5","key":"604_CR15","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.mcna.2014.06.009","volume":"98","author":"EL Sutton","year":"2014","unstructured":"Sutton EL. Psychiatric disorders and sleep issues. Med Clin North Am. 2014;98(5):1123\u201343.","journal-title":"Med Clin North Am."},{"issue":"3","key":"604_CR16","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jaad.2018.03.017","volume":"79","author":"ATM Ronnstad","year":"2018","unstructured":"Ronnstad ATM, Halling-Overgaard AS, Hamann CR, et al. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis. J Am Acad Dermatol. 2018;79(3):448-56.e30.","journal-title":"J Am Acad Dermatol."},{"issue":"2","key":"604_CR17","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jaad.2017.04.019","volume":"77","author":"L Eckert","year":"2017","unstructured":"Eckert L, Gupta S, Amand C, et al. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey. J Am Acad Dermatol. 2017;77(2):274-9.e3.","journal-title":"J Am Acad Dermatol."},{"issue":"1","key":"604_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20140712","volume":"462","author":"JJ Babon","year":"2014","unstructured":"Babon JJ, Lucet IS, Murphy JM, et al. The molecular regulation of Janus kinase (JAK) activation. Biochem J. 2014;462(1):1\u201313.","journal-title":"Biochem J."},{"issue":"12","key":"604_CR19","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","volume":"155","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Forman SB, Bissonnette R, et al. Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371\u20139.","journal-title":"JAMA Dermatol."},{"issue":"10246","key":"604_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255\u201366.","journal-title":"Lancet"},{"issue":"8","key":"604_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):1\u201311.","journal-title":"JAMA Dermatol."},{"issue":"2","key":"604_CR22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40271-016-0196-6","volume":"10","author":"C Copley-Merriman","year":"2017","unstructured":"Copley-Merriman C, Zelt S, Clark M, et al. Impact of measuring patient-reported outcomes in dermatology drug development. Patient. 2017;10(2):203\u201313.","journal-title":"Patient."},{"key":"604_CR23","unstructured":"Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH). Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009. https:\/\/www.fda.gov\/media\/77832\/download. Accessed 16 Dec 2020."},{"issue":"6","key":"604_CR24","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/bjd.13237","volume":"171","author":"JR Chalmers","year":"2014","unstructured":"Chalmers JR, Schmitt J, Apfelbacher C, et al. Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema\/dermatitis clinical trials (HOME). Br J Dermatol. 2014;171(6):1318\u201325.","journal-title":"Br J Dermatol."},{"key":"604_CR25","unstructured":"More Than Skin Deep Initiative. Understanding the lived experience of eczema: more than skin deep \u201cvoice of patient\u201d report. 2020. http:\/\/www.morethanskindeep-eczema.org\/uploads\/1\/2\/5\/3\/125377765\/mtsd_report_-_digital_file_1.pdf. Accessed 16 Dec 2020."},{"issue":"1","key":"604_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","volume":"10","author":"JM Hanifin","year":"2001","unstructured":"Hanifin JM, Thurston M, Omoto M, et al. The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10(1):11\u20138.","journal-title":"Exp Dermatol."},{"issue":"4","key":"604_CR27","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjd.17744","volume":"181","author":"G Yosipovitch","year":"2019","unstructured":"Yosipovitch G, Reaney M, Mastey V, et al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761\u20139.","journal-title":"Br J Dermatol."},{"issue":"7","key":"604_CR28","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1176\/ajp.2007.164.7.1035","volume":"164","author":"K Posner","year":"2007","unstructured":"Posner K, Oquendo MA, Gould M, et al. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA\u2019s pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007;164(7):1035\u201343.","journal-title":"Am J Psychiatry."},{"issue":"4","key":"604_CR29","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1177\/107319110100800409","volume":"8","author":"A Osman","year":"2001","unstructured":"Osman A, Bagge CL, Gutierrez PM, et al. The Suicidal Behaviors Questionnaire-Revised (SBQ-R): validation with clinical and nonclinical samples. Assessment. 2001;8(4):443\u201354.","journal-title":"Assessment"},{"issue":"1\u20133","key":"604_CR30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jad.2008.06.026","volume":"114","author":"K Kroenke","year":"2009","unstructured":"Kroenke K, Strine TW, Spitzer RL, et al. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009;114(1\u20133):163\u201373.","journal-title":"J Affect Disord."},{"issue":"5","key":"604_CR31","doi-asserted-by":"publisher","first-page":"502","DOI":"10.2340\/00015555-1246","volume":"92","author":"NQ Phan","year":"2021","unstructured":"Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prosepctive study on validty and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2021;92(5):502\u20137.","journal-title":"Acta Derm Venereol."},{"issue":"6","key":"604_CR32","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.anai.2018.07.040","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Chiesa Fuxench ZC, Gelfand JM, et al. Content and construct validity, predictors, and distribution of self-reported atopic dermatitis severity in US adults. Ann Allergy Asthma Immunol. 2018;121(6):729-34.e4.","journal-title":"Ann Allergy Asthma Immunol."},{"issue":"2","key":"604_CR33","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/all.13309","volume":"73","author":"PP Vakharia","year":"2018","unstructured":"Vakharia PP, Chopra R, Sacotte R, et al. Validation of patient-reported global severity of atopic dermatitis in adults. Allergy. 2018;73(2):451\u20138.","journal-title":"Allergy"},{"key":"604_CR34","first-page":"e44","volume":"179","author":"MG Lebwohl","year":"2018","unstructured":"Lebwohl MG, Simpson EL, Bushmakin AG, et al. Validation of the pruritus and symptoms assessment for atopic dermatitis in adults with moderate to severe atopic dermatitis [ISAD abstract P071]. Br J Dermatol. 2018;179:e44.","journal-title":"Br J Dermatol."},{"issue":"12","key":"604_CR35","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","volume":"140","author":"CR Charman","year":"2004","unstructured":"Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients\u2019 perspective. Arch Dermatol. 2004;140(12):1513\u20139.","journal-title":"Arch Dermatol."},{"key":"604_CR36","doi-asserted-by":"crossref","unstructured":"Ersser SJ, Cowdell F, Latter S, et al. Psychological and educational interventions for atopic eczema in children. Cochrane Database Syst Rev. 2014; 2014(1):CD004054.","DOI":"10.1002\/14651858.CD004054.pub3"},{"issue":"6","key":"604_CR37","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.jaci.2007.08.011","volume":"120","author":"J Schmitt","year":"2007","unstructured":"Schmitt J, Langan S, Williams HC. What are the best outcome measurements for atopic eczema? A systematic review. J Allergy Clin Immunol. 2007;120(6):1389\u201398.","journal-title":"J Allergy Clin Immunol."},{"issue":"3","key":"604_CR38","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol."},{"issue":"6","key":"604_CR39","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/j.1365-2133.1995.tb16953.x","volume":"132","author":"MS Lewis-Jones","year":"1995","unstructured":"Lewis-Jones MS, Finlay AY. The Children\u2019s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942\u20139.","journal-title":"Br J Dermatol."},{"issue":"6","key":"604_CR40","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361\u201370.","journal-title":"Acta Psychiatr Scand."},{"key":"604_CR41","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1192\/bjp.175.5.452","volume":"175","author":"D White","year":"1999","unstructured":"White D, Leach C, Sims R, et al. Validation of the Hospital Anxiety and Depression Scale for use with adolescents. Br J Psychiatry. 1999;175:452\u20134.","journal-title":"Br J Psychiatry."},{"key":"604_CR42","unstructured":"Ware JE.\u00a0User\u2019s manual for the SF-36v2 health survey. Lincoln, RI: QualityMetric Incorporated; 2008."},{"issue":"10","key":"604_CR43","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res."},{"issue":"6","key":"604_CR44","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s11136-010-9649-x","volume":"19","author":"U Ravens-Sieberer","year":"2010","unstructured":"Ravens-Sieberer U, Wille N, Badia X, et al. Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study. Qual Life Res. 2010;19(6):887\u201397.","journal-title":"Qual Life Res."},{"issue":"2","key":"604_CR45","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/cncr.10245","volume":"94","author":"D Cella","year":"2002","unstructured":"Cella D, Lai JS, Chang CH, et al. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94(2):528\u201338.","journal-title":"Cancer"},{"issue":"7","key":"604_CR46","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/MPH.0b013e318095057a","volume":"29","author":"JS Lai","year":"2007","unstructured":"Lai JS, Cella D, Kupst MJ, et al. Measuring fatigue for children with cancer: development and validation of the pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (pedsFACIT-F). J Pediatr Hematol Oncol. 2007;29(7):471\u20139.","journal-title":"J Pediatr Hematol Oncol."},{"issue":"5","key":"604_CR47","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics"},{"key":"604_CR48","doi-asserted-by":"crossref","unstructured":"Kim BS, Silverberg JI, St\u00e4nder S, et al. Rapid improvement of itch associated with atopic dermatitis with abrocitinib is partially independent of overall disease improvement: results from pooled phase 2b and 3 monotherapy studies. Dermatitis. 2021 (In press).","DOI":"10.1097\/DER.0000000000000770"},{"issue":"4","key":"604_CR49","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/MLR.0b013e3181c162a2","volume":"48","author":"N Luo","year":"2010","unstructured":"Luo N, Johnson J, Coons SJ. Using instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instruments. Med Care. 2010;48(4):365\u201371.","journal-title":"Med Care."},{"issue":"1","key":"604_CR50","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1398-9995.2011.02719.x","volume":"67","author":"ME Schram","year":"2012","unstructured":"Schram ME, Spuls PI, Leeflang MM, et al. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67(1):99\u2013106.","journal-title":"Allergy"},{"issue":"6","key":"604_CR51","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1001\/jamadermatol.2020.0796","volume":"156","author":"AM Drucker","year":"2020","unstructured":"Drucker AM, Ellis AG, Bohdanowicz M, et al. Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis. JAMA Dermatol. 2020;156(6):659\u201367.","journal-title":"JAMA Dermatol."},{"issue":"6","key":"604_CR52","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.jaad.2020.02.060","volume":"82","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Yosipovitch G, Simpson EL, et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate-to-severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 & SOLO 2, AD ADOL, and CHRONOS. J Am Acad Dermatol. 2020;82(6):1328\u201336.","journal-title":"J Am Acad Dermatol."},{"issue":"12","key":"604_CR53","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JL, et al. Abrocitinib versus placebo and dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101-1112.","journal-title":"N Engl J Med"},{"key":"604_CR54","doi-asserted-by":"publisher","unstructured":"Reich K, DeLozier AM, Nunes FP, et al. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. J Dermatolog Treat. 2020;1\u201310. https:\/\/doi.org\/10.1080\/09546634.2020.1839008","DOI":"10.1080\/09546634.2020.1839008"},{"issue":"2","key":"604_CR55","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jaad.2018.08.063","volume":"80","author":"KR Patel","year":"2019","unstructured":"Patel KR, Immaneni S, Singam V, et al. Association between atopic dermatitis, depression, and suicidal ideation: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80(2):402\u201310.","journal-title":"J Am Acad Dermatol."}],"updated-by":[{"DOI":"10.1007\/s40257-021-00634-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000}}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00604-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-021-00604-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00604-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T06:23:24Z","timestamp":1629267804000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-021-00604-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,5]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["604"],"URL":"https:\/\/doi.org\/10.1007\/s40257-021-00604-9","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40257-021-00634-3","asserted-by":"object"}]},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,5]]},"assertion":[{"value":"30 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40257-021-00634-3","URL":"https:\/\/doi.org\/10.1007\/s40257-021-00634-3","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jonathan I. Silverberg has served as an investigator for Celgene, Eli Lilly, F. Hoffmann-LaRoche, Menlo Therapeutics, Realm Therapeutics, Regeneron, and Sanofi; as a consultant for Pfizer Inc., AbbVie, Anacor, AnaptysBio, Arena Pharmaceuticals, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Glenmark, Incyte, Kiniksa, LEO Pharma, Menlo Therapeutics, Novartis, Realm Therapeutics, Regeneron, and Sanofi; and as a speaker for Regeneron and Sanofi. Jacob P. Thyssen is an advisor\/investigator or speaker for Pfizer, AbbVie, Eli Lilly, LEO Pharma, Regeneron, and Sanofi-Genzyme. Eric L. Simpson is a consultant for Pfizer, AbbVie, Celgene, Eli Lilly, Galderma, GlaxoSmithKline, Menlo Therapeutics, LEO Pharma, and Regeneron and a principal investigator for AbbVie, GlaxoSmithKline, LEO Pharma, Novartis, Regeneron, Tioga Pharmaceuticals, and Vanda Pharmaceuticals. Gil Yosipovitch has been a consultant and advisor for Bellus, Pfizer, Eli Lilly, Galderma, LEO Pharma, Kiniksa Pharmaceuticals, Menlo Therapeutics, Novartis, Sanofi-Regeneron, and Trevi Therapeutics, and a principal investigator for Pfizer, Galderma, Kiniksa Pharmaceuticals, LEO Pharma, Sanofi-Regeneron, Novartis, and Sun Pharmaceutical Industries. Sonja St\u00e4nder is a consultant and\/member of advisory boards for Pfizer Inc., Almirall, Bayer, Beiersdorf, Bellus Health, Bionorica, Cara Therapeutics, Celgene, Clexio, DS Biopharma, Galderma, Menlo Therapeutics, Novartis, Nuformix, Perrigo, Sanofi, Sienna Biopharmaceutical, Trevi Therapeutics, and Vifor Pharma; has received research grants from the German Research Foundation (DFG), the European Academy of Dermatology and Venereology (EADV), Almirall, Beiersdorf, Galderma, LEO Pharma, Kiniksa Pharmaceuticals, Menlo Therapeutics, Novartis, Sanofi, and Trevi Therapeutics; and has been an investigator for Dermasence, Galderma, Kiniksa Pharmaceuticals, Menlo Therapeutics, Novartis, Sanofi, Trevi Therapeutics, and Vanda Pharmaceuticals. Hernan Valdez, Ricardo Rojo, Pinaki Biswas, Daniela E. Myers, Claire Feeney, and Marco DiBonaventura are employees and shareholders of Pfizer Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The institutional review board at each study site approved the study protocol and written informed consent was provided by parents\/legal guardians. The study was conducted in accordance with the protocol, local legal and regulatory requirements, and the general principles set forth in the International Ethical Guidelines for Biomedical Research Involving Human Subjects, International Conference on Harmonisation Guideline for Good Clinical Practice, and the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was provided by the participants of all studies.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Upon request, and subject to certain criteria, conditions, and exceptions (see  for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines, and medical devices (1) for indications that have been approved in the USA and\/or the European Union or (2) in programs that have been terminated (i.e., development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24 months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"All authors contributed to the design of the study; participated in the acquisition, analysis, and\/or interpretation of data; reviewed and critically revised the report for important intellectual content; and gave final approval of the version that was submitted.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}